Sanuwave announces preliminary Q4 2024 revenue of $10.1-10.3M, record high, up 44-47% YoY

SANUWAVE Health, Inc.

2024-FY EPS reported -$7.03 revenue$32,634,000

Q4 2024 revenue expected $10.1-10.3M, highest quarterly revenue in company history; increase of 44-47% YoY.
UltraMist revenue up >54% vs Q4 2023, representing ~98% of total Q4 revenue; applicator sales all-time record ~58% of total.
Full year 2024 preliminary revenue $32.4-32.6M, up 59-60% vs 2023.
CEO Morgan Frank cites third consecutive record quarter and 'breakout year' targeting rapid profitable growth.
Company expects to release complete Q4 and FY2024 results in March 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.